The company said, “McKesson (MCK) is updating its long-term growth targets and introducing segment-specific targets for the new reporting structure. McKesson is also updating and increasing its long-term Adjusted Earnings per Diluted Share growth target to 13% to 16%, an increase from the prior range of 12% to 14%. This reflects the strength of McKesson’s leading platforms in oncology, multispecialty, and biopharma solutions, supported by operating leverage and efficient capital deployment.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strategic Positioning and Growth Potential Justify Buy Rating
- McKesson announces changes to reportable segments, organizational structure
- McKesson’s Strategic Restructuring and Growth Potential Earns ‘Buy’ Rating from Analyst
- McKesson Announces New Reporting Segments Restructure
- McKesson price target raised to $772 from $766 at Wells Fargo